Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC

INTRODUCTION: Studies have shown improved tolerability with once-weekly versus three-weekly docetaxel in the second-line treatment of advanced non-small cell lung cancer (NSCLC). This study aimed to evaluate the tolerability of nintedanib plus weekly docetaxel in patients with NSCLC. METHODS: This p...

Descripción completa

Detalles Bibliográficos
Autores principales: Westeel, Virginie, Schuette, Wolfgang, Urban, Thierry, Radonjic, Dejan, von Wangenheim, Ute, Lorence, Robert M., Reck, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581470/
https://www.ncbi.nlm.nih.gov/pubmed/37847688
http://dx.doi.org/10.1371/journal.pone.0292307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581470/
https://www.ncbi.nlm.nih.gov/pubmed/37847688
http://dx.doi.org/10.1371/journal.pone.0292307

Ejemplares similares